FOSTER CITY, Calif.--(BUSINESS WIRE)--Mar. 13, 2009--
Gilead Sciences, Inc. (Nasdaq:GILD) announced today that, after
conducting an investigation, the United States Department of Justice
(“DOJ”) has notified the United States District Court for the Northern
District of California “of its decision not to intervene” in a lawsuit
filed by a former Gilead employee under the qui tam provisions of
the federal False Claims Act. The DOJ has also notified Gilead of its
decision to decline to intervene in two additional False Claims Act
lawsuits. If the plaintiffs in these lawsuits decide to pursue their
allegations further, Gilead will defend the matters vigorously.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. The company’s mission is to advance the care of patients suffering
from life-threatening diseases worldwide. Headquartered in Foster City,
California, Gilead has operations in North America, Europe and Australia.
This press release includes forward-looking statements, within the
meaning of the Private Securities Litigation Reform Act of 1995, that
are subject to risks, uncertainties and other factors, including the
risks associated with being a party to any litigation matter and the
inability to predict the outcome. These risks, uncertainties and other
factors are described in the reports and other documents filed by Gilead
with the Securities and Exchange Commission and could cause actual
results to differ materially from those referred to in the
forward-looking statements. The reader is cautioned not to rely on these
forward-looking statements. All forward-looking statements are based on
information currently available to Gilead, and Gilead assumes no
obligation to update any such forward-looking statements or other
statements included in this press release.
For more information on Gilead Sciences, please visit the company's
website at www.gilead.com
or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Source: Gilead Sciences, Inc.
Gilead Sciences, Inc.Susan Hubbard, 650-522-5715 (Investors)Cara
Miller, 650-522-1616 (Media)
